Atossa Therapeutics/$ATOS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Atossa Therapeutics
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Ticker
$ATOS
Sector
Primary listing
Employees
15
Headquarters
Website
ATOS Metrics
BasicAdvanced
$34M
-
-$3.52
1.34
-
Price and volume
Market cap
$34M
Beta
1.34
52-week high
$7.56
52-week low
$3.76
Financial strength
Current ratio
6.769
Quick ratio
6.303
Profitability
EBITDA (TTM)
-32.84
Management effectiveness
Return on assets (TTM)
-29.87%
Return on equity (TTM)
-48.89%
Valuation
Price to book
0.68
Price to tangible book (TTM)
0.68
Price to free cash flow (TTM)
-1.284
Free cash flow yield (TTM)
-77.87%
Free cash flow per share (TTM)
-3.068
Growth
Earnings per share change (TTM)
9.53%
3-year earnings per share growth (CAGR)
6.96%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Atossa Therapeutics stock?
Atossa Therapeutics (ATOS) has a market cap of $34M as of February 13, 2026.
What is the P/E ratio for Atossa Therapeutics stock?
The price to earnings (P/E) ratio for Atossa Therapeutics (ATOS) stock is 0 as of February 13, 2026.
Does Atossa Therapeutics stock pay dividends?
No, Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders as of February 13, 2026.
When is the next Atossa Therapeutics dividend payment date?
Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders.
What is the beta indicator for Atossa Therapeutics?
Atossa Therapeutics (ATOS) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.